Skip to main content
. Author manuscript; available in PMC: 2011 Nov 4.
Published in final edited form as: Neuron. 2010 Nov 4;68(3):428–441. doi: 10.1016/j.neuron.2010.10.020

Figure 8.

Figure 8

Inhibiting γ-secretase cleavage to reduce Aβ production normalizes EPM behavior in 4-month-old EC-APP mice. Mice were injected once a day with LY-411575 (3mg/kg) or vehicle on two consecutive days and tested in the EPM 6–8 h after the second injection. (A) Vehicle-treated EC-APP (tTA/tet) mice spent more time in the open arms of the EPM than vehicle-treated NTG mice. LY-411575 treatment significantly reduced the amount of time EC-APP mice spent in the open arms to the levels in vehicle-treated NTG controls. n=5–7 mice/group. p<0.005 for the interaction effect between genotype and treatment by 2-way ANOVA, *p<0.05 vs. NTG+vehicle or as indicated by bracket (one-way ANOVA followed by Tukey post-hoc test). (B) APP CTFs in the EC of EC-APP mice were measured by Western blotting and quantified by densitometry. Inhibition of γ-secretase cleavage increased CTF levels in EC-APP mice. n=5–7 mice/group. **p<0.005 vs. vehicle by t test. Values are mean ± SEM.